免疫检查点抑制剂在肿瘤治疗中的应用

The Treatment of Malignant Tumor by Immune Checkpoint Inhibitors

免疫治疗是继手术、放疗、化疗、分子靶向治疗后又一种能够改善恶性肿瘤患者生存的手段,在各种免疫治疗方式之中,免疫检查点抑制剂是近几年获得突出疗效的药物。目前,我们对于CTLA-4和PD-1/PD-L1两个免疫检查点通路有了比较深入的研究并且有多种针对上述通路的抑制剂。本文对相关的免疫检查点抑制剂治疗多种肿瘤的临床试验结果进行简单的综述,阐述它们在在恶性黑色素瘤、支气管肺癌、前列腺癌、肾细胞癌以及霍奇金淋巴瘤治疗中的作用。

Immunotherapy is an important treatment followed surgery, radiotherapy, chemotherapy and target therapy, which can improve survival of patients with malignant tumor. Immune checkpoint inhibitors are kinds of medicine which show their high efficacy in melanoma, lung cancer, prostate cancer, renal cell carcinoma and Hodgkin＇s lymphoma. Two immune checkpoint pathway involved CTLA-4 and PD-1/PD-L1 have been well studied and some inhibitors of them have been manufactured. We reviewed the clinical studies about these immune checkpoint inhibitors in tumors described above.